Drug profile · INN
epoprostenol sodium
EPOPROSTENOL ACT PARTIAL CHANGE APPROVAL
epoprostenol sodium (EPOPROSTENOL ACT PARTIAL CHANGE APPROVAL) is a prostanoid ip receptor agonist. Route of administration: injection. Current US regulatory status: approved.
Drug details — epoprostenol sodium
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
epoprostenol sodium (EPOPROSTENOL ACT PARTIAL CHANGE APPROVAL) is a prostanoid ip receptor agonist. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Prostanoid IP receptor agonist
Primary target: Prostacyclin receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is epoprostenol sodium?
epoprostenol sodium (EPOPROSTENOL ACT PARTIAL CHANGE APPROVAL) is a prostanoid ip receptor agonist. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for epoprostenol sodium?
EPOPROSTENOL ACT PARTIAL CHANGE APPROVAL is a marketed brand name for epoprostenol sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of epoprostenol sodium?
epoprostenol sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.